✦ LIBER ✦

A comparison of individualized treatment guided by VeriStrat with standard of care treatment strategies in patients receiving second-line treatment for advanced non-small cell lung cancer: A cost-utility analysis

✍ Scribed by Nelson, Richard E.; Stenehjem, David; Akerley, Wallace

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

PCN90 Cost-Effectiveness Analysis of Erl

✍ Nguyen, T.T.T.; Yagudina, R.; Kulikov, A. 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 58 KB

Prospective Observational Comparison of

✍ Pennella, Eduardo; Obasaju, Coleman K.; Pohl, Gerhardt; Peltz, Gerson; Girvan, A 📂 Article 📅 2013 🏛 CIG Media Group, LP. 🌐 English ⚖ 681 KB

Erlotinib or best supportive care for th

✍ Cromwell, Ian; van der Hoek, Kimberly; Malfair Taylor, Suzanne C.; Melosky, Barb 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 396 KB

Second-line with vinorelbine in the week

✍ Santoro, A.; Maiorino, L.; Santoro, M. 📂 Article 📅 1994 🏛 Elsevier Science 🌐 English ⚖ 130 KB

A cross-market cost comparison of erloti

✍ Nuijten, Mark J.C.; de Castro Carpeño, Javier; Chouaid, Christos; Vergnenègre, A 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 375 KB

PCN10 COST-EFFCTIVENESS ANALYSIS OF ERLO

✍ TC Hsia; GC Chang; YM Chen; MC Lin; WC Su; CM Tsai; CM Tsai; L Yang; J Creeden 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 71 KB